The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC). This is an ASCO Meeting Abstract from ...

Therefore, by demonstrating that there exists a straightforward pathway for ATI-2307 resistance to arise, our findings may support further precautionary measures in the clinical use of ATI-2307. Media ...